Abstract Featuring CivaSheet® Radiation Device Wins Multiple ABS World Congress Awards

CivaTech Oncology recently received notification that a scientific abstract featuring its new, FDA cleared CivaSheet® radiation therapy device was awarded “Best of Show – Physics” at the American Brachytherapy Society’s 2016 World Congress of Brachytherapy. The abstract received the Judith Stitt award as one of the top four abstracts submitted to the conference out of 400+ total submissions, and will be presented by its author at a special session during the upcoming ABS World Congress of Brachytherapy June 27 through 29 in San Francisco, CA.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160607005214/en/

Illustration from the Judith Stitt award winning abstract featuring CivaSheet. Note the reduced radiation dose to sensitive bowel tissue with CivaSheet when compared to traditional seed-based brachytherapy sources. (Photo: Business Wire

The winning abstract, titled “Low-Energy Brachytherapy Sources for Pelvic Sidewall Treatment” was submitted by Mark Rivard, Ph.D., Professor of Medical Physics at Tufts University School of Medicine. Dr. Rivard notes, “The abstract focuses on CivaSheet’s directional radiation properties when used to treat cancer in the pelvic sidewall region. Results from an actual patient implanted with the CivaSheet were compared to theoretical results assuming traditional radiation seeds. The results showed that the new directional CivaSheet provided good dose coverage to the target treatment region while drastically reducing unwanted collateral radiation dose to sensitive and healthy bowel tissues when compared to traditional therapy devices.”

CivaSheet is a flexible, low-dose rate (LDR) implantable brachytherapy device. The device is constructed with bio-absorbable materials using CivaTech’s patented and propriety methods to construct polymer-encapsulated radiation sources. The CivaSheet emits directional radiation by integrating exclusive gold shielding. This directional property allows physicians to deliver aggressive radiation doses immediately adjacent to healthy, sensitive tissues. It also enables physicians to deliver focused radiation doses to patients who may have already received dose limits from external-beam radiation, thus expanding options to patients with advanced or recurrent disease.

Also of note, three other abstracts featuring CivaSheet will be presented at the 2016 World Congress of Brachytherapy. Details are available on the CivaTech Oncology website.

About CivaTech Oncology® Inc.

CivaTech Oncology® designs innovative products that bring meaningful improvements to low dose rate brachytherapy. For more information, please visit www.civatechoncology.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160607005214/en/